Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other financing activities (2016 - 2025)

Cytokinetics (CYTK) has disclosed Other financing activities for 14 consecutive years, with -$17.2 million as the latest value for Q4 2025.

  • Quarterly Other financing activities changed N/A to -$17.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.5 million for FY2025, 87.49% down from the prior year.
  • Other financing activities for Q4 2025 was -$17.2 million at Cytokinetics, down from $720000.0 in the prior quarter.
  • The five-year high for Other financing activities was $18.4 million in Q1 2024, with the low at -$17.2 million in Q4 2025.
  • Average Other financing activities over 5 years is $3.9 million, with a median of $4.4 million recorded in 2021.
  • The sharpest move saw Other financing activities skyrocketed 115.82% in 2022, then increased 9.53% in 2023.
  • Over 5 years, Other financing activities stood at $4.4 million in 2021, then surged by 115.82% to $9.6 million in 2022, then grew by 9.53% to $10.5 million in 2023, then skyrocketed by 75.42% to $18.4 million in 2024, then tumbled by 193.38% to -$17.2 million in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at -$17.2 million, $720000.0, and $514000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.